Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T14597
|
||||
Former ID |
TTDS00249
|
||||
Target Name |
Receptor protein-tyrosine kinase erbB-2
|
||||
Gene Name |
ERBB2
|
||||
Synonyms |
C-erbB-2; C-erbB-2 oncoprotein; Epidermal growth factor receptor 2; Erb2; HER-2; HER2 (erbB2/neu); HER2/neu; MLN 19; NEU proto-oncogene; P185erbB2; Tyrosine kinase receptor ErbB2; Tyrosine kinase-type cell surface receptor HER2; ERBB2
|
||||
Target Type |
Successful
|
||||
Disease | Advanced breast cancer [ICD9: 174, 175; ICD10: C50] | ||||
Asthma; Breast cancer [ICD9:174, 175; ICD10: J45, C50] | |||||
Bladder cancer [ICD9: 188; ICD10: C67] | |||||
Breast cancer; Gastric cancer [ICD9:174, 175, 151; ICD10: C50, C16] | |||||
Breast cancer [ICD9: 174, 175; ICD10: C50] | |||||
Colorectal cancer; HER2-positive urogenital cancer [ICD9:153, 154, 179-186; ICD10: C18-C21, C50-C68] | |||||
Cancer [ICD9: 140-229; ICD10: C00-C96] | |||||
Gastrointestinal cancers [ICD9: 150-159; ICD10: C15-C26] | |||||
Glioblastoma multiforme [ICD9: 191; ICD10: C71] | |||||
Gastric cancer [ICD9: 151; ICD10: C16] | |||||
Head and neck squamous cell carcinoma [ICD9: 199; ICD10: C44] | |||||
Inflammatory breast cancer [ICD9: 174, 175; ICD10: C50] | |||||
Lymphoma [ICD9: 202.8, 208.9; ICD10: C81-C86] | |||||
Malignant tumor [ICD9: 140-199; ICD10: C00-C75, C7A, C7B] | |||||
Metastatic breast cancer [ICD10: C50] | |||||
Non-hodgkin's lymphoma [ICD10: C85] | |||||
Non-small cell lung cancer [ICD10: C33-C34] | |||||
Prostate cancer [ICD9: 185; ICD10: C61] | |||||
Retinal venous occlusion [ICD10: H34.8] | |||||
Refractory breast cancer [ICD9: 174, 175; ICD10: C50] | |||||
Solid tumours [ICD9: 140-199, 210-229; ICD10: C00-D48] | |||||
Unspecified [ICD code not available] | |||||
Function |
In the nucleus is involved intranscriptional regulation. Associates with the 5'-TCAAATTC-3' sequence in the PTGS2/COX-2 promoter and activates its transcription. Implicated in transcriptional activation of CDKN1A; the function involves STAT3 and SRC. Involved in the transcription of rRNA genes by RNA Pol I and enhances protein synthesis and cell growth.
|
||||
BioChemical Class |
Kinase
|
||||
Target Validation |
T14597
|
||||
UniProt ID | |||||
EC Number |
EC 2.7.10.1
|
||||
Sequence |
MELAALCRWGLLLALLPPGAASTQVCTGTDMKLRLPASPETHLDMLRHLYQGCQVVQGNL
ELTYLPTNASLSFLQDIQEVQGYVLIAHNQVRQVPLQRLRIVRGTQLFEDNYALAVLDNG DPLNNTTPVTGASPGGLRELQLRSLTEILKGGVLIQRNPQLCYQDTILWKDIFHKNNQLA LTLIDTNRSRACHPCSPMCKGSRCWGESSEDCQSLTRTVCAGGCARCKGPLPTDCCHEQC AAGCTGPKHSDCLACLHFNHSGICELHCPALVTYNTDTFESMPNPEGRYTFGASCVTACP YNYLSTDVGSCTLVCPLHNQEVTAEDGTQRCEKCSKPCARVCYGLGMEHLREVRAVTSAN IQEFAGCKKIFGSLAFLPESFDGDPASNTAPLQPEQLQVFETLEEITGYLYISAWPDSLP DLSVFQNLQVIRGRILHNGAYSLTLQGLGISWLGLRSLRELGSGLALIHHNTHLCFVHTV PWDQLFRNPHQALLHTANRPEDECVGEGLACHQLCARGHCWGPGPTQCVNCSQFLRGQEC VEECRVLQGLPREYVNARHCLPCHPECQPQNGSVTCFGPEADQCVACAHYKDPPFCVARC PSGVKPDLSYMPIWKFPDEEGACQPCPINCTHSCVDLDDKGCPAEQRASPLTSIISAVVG ILLVVVLGVVFGILIKRRQQKIRKYTMRRLLQETELVEPLTPSGAMPNQAQMRILKETEL RKVKVLGSGAFGTVYKGIWIPDGENVKIPVAIKVLRENTSPKANKEILDEAYVMAGVGSP YVSRLLGICLTSTVQLVTQLMPYGCLLDHVRENRGRLGSQDLLNWCMQIAKGMSYLEDVR LVHRDLAARNVLVKSPNHVKITDFGLARLLDIDETEYHADGGKVPIKWMALESILRRRFT HQSDVWSYGVTVWELMTFGAKPYDGIPAREIPDLLEKGERLPQPPICTIDVYMIMVKCWM IDSECRPRFRELVSEFSRMARDPQRFVVIQNEDLGPASPLDSTFYRSLLEDDDMGDLVDA EEYLVPQQGFFCPDPAPGAGGMVHHRHRSSSTRSGGGDLTLGLEPSEEEAPRSPLAPSEG AGSDVFDGDLGMGAAKGLQSLPTHDPSPLQRYSEDPTVPLPSETDGYVAPLTCSPQPEYV NQPDVRPQPPSPREGPLPAARPAGATLERPKTLSPGKNGVVKDVFAFGGAVENPEYLTPQ GGAAPQPHPPPAFSPAFDNLYYWDQDPPERGAPPSTFKGTPTAENPEYLGLDVPV |
||||
Structure |
1MFG; 1MFL; 1MW4; 1N8Z; 1OVC; 1QR1; 1S78; 2A91; 2JWA; 2KS1; 2L4K; 3BE1; 3H3B; 3MZW; 3N85; 3PP0; 3RCD; 4GFU; 4HRL; 4HRM; 4HRN; 1MFG; 1MFL; 1MW4; 1N8Z; 1OVC;1QR1; 1S78; 2A91; 2JWA; 2KS1; 2L4K; 3BE1; 3H3B; 3MZW; 3N85; 3PP0; 3RCD; 4GFU; 4HRL; 4HRM; 4HRN
|
||||
Drugs and Mode of Action | |||||
Drug(s) | BIBW 2992 | Drug Info | Approved | Non-small cell lung cancer | [529823], [541010] |
Lapatinib | Drug Info | Approved | Breast cancer | [538586], [541034] | |
Masoprocol | Drug Info | Approved | Prostate cancer | [467601], [536361] | |
Pertuzumab | Drug Info | Approved | Breast cancer | [468138], [532320] | |
Trastuzumab | Drug Info | Approved | Asthma; Breast cancer | [468150], [532651], [536361] | |
Tyverb/Tykerb | Drug Info | Approved | Refractory breast cancer | [538585] | |
Bevacizumab + Trastuzumab | Drug Info | Phase 3 | Metastatic breast cancer | [532301] | |
Dacomitinib | Drug Info | Phase 3 | Non-small cell lung cancer | [523496], [542446] | |
HKI-272 | Drug Info | Phase 3 | Breast cancer | [548009] | |
Nelipepimut | Drug Info | Phase 3 | Non-hodgkin's lymphoma | [523700] | |
NeuVax | Drug Info | Phase 3 | Breast cancer | [523700] | |
PF-05280014 | Drug Info | Phase 3 | Breast cancer | [524830] | |
Taxol/Paraplatin/Herceptin | Drug Info | Phase 3 | Breast cancer | [528260] | |
Trastuzumab-DM1 | Drug Info | Phase 3 | Breast cancer | [532548] | |
Tyverb/Tykerb | Drug Info | Phase 3 | Gastric cancer | [538585] | |
Anti-CD3 and anti-Her2/neu bispecific antibody-armed activated T cells | Drug Info | Phase 2 | Breast cancer | [549995] | |
AZD8931 | Drug Info | Phase 2 | Breast cancer | [524722], [542691] | |
Bevacizumab + Trastuzumab | Drug Info | Phase 2 | Breast cancer | [554002] | |
BMS-599626 | Drug Info | Phase 2 | Solid tumours | [523940], [542630] | |
CI-1033 | Drug Info | Phase 2 | Lymphoma | [525738], [541018] | |
CP-724714 | Drug Info | Phase 2 | Lymphoma | [521628], [542808] | |
DN24-02 | Drug Info | Phase 2 | Colorectal cancer; HER2-positive urogenital cancer | [523475] | |
Ertumaxomab | Drug Info | Phase 2 | Breast cancer | [529707], [531972] | |
HER-2 Protein AutoVac | Drug Info | Phase 2 | Breast cancer | [531718] | |
Her2-targeted autologous T-cell therapy | Drug Info | Phase 2 | Glioblastoma multiforme | [532563] | |
HER2/neu peptide vaccine | Drug Info | Phase 2 | Breast cancer | [524128] | |
HM-78136B | Drug Info | Phase 2 | Solid tumours | [524875], [542826] | |
Margetuximab | Drug Info | Phase 2 | Gastrointestinal cancers | [524257], [543243] | |
MGAH22 | Drug Info | Phase 2 | Solid tumours | [524257] | |
MM-111 | Drug Info | Phase 2 | Breast cancer; Gastric cancer | [524196] | |
Pazopanib + Tyverb/Tykerb | Drug Info | Phase 2 | Inflammatory breast cancer | [532156] | |
Tyverb/Tykerb | Drug Info | Phase 2 | Head and neck squamous cell carcinoma | [538585] | |
ABY-025 | Drug Info | Phase 1/2 | Bladder cancer | [524300] | |
AGN-208397 | Drug Info | Phase 1/2 | Retinal venous occlusion | [522883] | |
AVX901 | Drug Info | Phase 1/2 | Breast cancer | [523789] | |
Varlitinib | Drug Info | Phase 1/2 | Breast cancer | [522608], [542628] | |
S-222611 | Drug Info | Phase 1b | Malignant tumor | [551683] | |
ARRY-380 | Drug Info | Phase 1 | Cancer | [524395] | |
Cipatinib | Drug Info | Phase 1 | Cancer | [523370] | |
CUDC-101 | Drug Info | Phase 1 | Solid tumours | [533101] | |
Ertumaxomab | Drug Info | Phase 1 | Advanced breast cancer | [889343] | |
HER2p63-71 peptide vaccine | Drug Info | Phase 1 | Cancer | [525850] | |
JNJ-26483327 | Drug Info | Phase 1 | Cancer | [522319] | |
MM-302 | Drug Info | Phase 1 | Breast cancer | [523378] | |
MVA HER-2 AutoVac | Drug Info | Phase 1 | Breast cancer | [523092] | |
Recombinant human Erbb3 fragment therapeutic tumor vaccine | Drug Info | Phase 1 | Cancer | [551788] | |
TAK-285 | Drug Info | Phase 1 | Cancer | [522127] | |
TrasGEX | Drug Info | Phase 1 | Cancer | [523579] | |
VM-206 | Drug Info | Phase 1 | Cancer | [524352] | |
Zemab | Drug Info | Phase 1 | Cancer | [548526] | |
Her-2-Bi-armed ATC | Drug Info | Discontinued in Phase 2 | Breast cancer | [548761] | |
TAK165 | Drug Info | Discontinued in Phase 1 | Cancer | [541276], [547786] | |
GW-974 | Drug Info | Terminated | Breast cancer | [546750] | |
Inhibitor | (1-Benzyl-1H-indazol-5-yl)-quinazolin-4-yl-amine | Drug Info | [526072] | ||
(1-Benzyl-1H-indol-5-yl)-quinazolin-4-yl-amine | Drug Info | [526072] | |||
AGN-208397 | Drug Info | [532414] | |||
AVX901 | Drug Info | [523789] | |||
AZD8931 | Drug Info | [550278], [550288] | |||
BIBW 2992 | Drug Info | [550386] | |||
BMS-599626 | Drug Info | [536474] | |||
CI-1033 | Drug Info | [536474] | |||
CP-724714 | Drug Info | [536474] | |||
GW-974 | Drug Info | [550119] | |||
HER-2 Protein AutoVac | Drug Info | [531718] | |||
Her2-targeted autologous T-cell therapy | Drug Info | [532879] | |||
HKI-272 | Drug Info | [536474] | |||
HM-78136B | Drug Info | [531542] | |||
JNJ-26483327 | Drug Info | [550422] | |||
Lapatinib | Drug Info | [536331], [537224] | |||
Nelipepimut | Drug Info | [532798] | |||
Pazopanib + Tyverb/Tykerb | Drug Info | [550963] | |||
Pertuzumab | Drug Info | [549951], [551607] | |||
S-222611 | Drug Info | [551683] | |||
TAK-285 | Drug Info | [551717] | |||
TAK165 | Drug Info | [536474] | |||
Taxol/Paraplatin/Herceptin | Drug Info | [527947] | |||
Tyverb/Tykerb | Drug Info | [550963] | |||
Enhancer | ABY-025 | Drug Info | [530980] | ||
Modulator | ARRY-380 | Drug Info | [549731] | ||
Cipatinib | Drug Info | [1572591] | |||
CUDC-101 | Drug Info | [533101] | |||
DN24-02 | Drug Info | [528989] | |||
Masoprocol | Drug Info | [556264] | |||
MGAH22 | Drug Info | [544225] | |||
MM-111 | Drug Info | [889442] | |||
MM-302 | Drug Info | [533224] | |||
PF 5208766 | Drug Info | ||||
Varlitinib | Drug Info | [1572591] | |||
Antagonist | Dacomitinib | Drug Info | [542446] | ||
PF-05280014 | Drug Info | [532875] | |||
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
Pathways | |||||
KEGG Pathway | ErbB signaling pathway | ||||
Calcium signaling pathway | |||||
HIF-1 signaling pathway | |||||
Focal adhesion | |||||
Adherens junction | |||||
Pathways in cancer | |||||
Proteoglycans in cancer | |||||
MicroRNAs in cancer | |||||
Pancreatic cancer | |||||
Endometrial cancer | |||||
Prostate cancer | |||||
Bladder cancer | |||||
Non-small cell lung cancer | |||||
Central carbon metabolism in cancer | |||||
NetPath Pathway | TCR Signaling Pathway | ||||
PANTHER Pathway | Cadherin signaling pathway | ||||
EGF receptor signaling pathway | |||||
Pathway Interaction Database | ErbB4 signaling events | ||||
ErbB2/ErbB3 signaling events | |||||
ErbB receptor signaling network | |||||
a6b1 and a6b4 Integrin signaling | |||||
Validated targets of C-MYC transcriptional repression | |||||
PathWhiz Pathway | Phosphatidylinositol Phosphate Metabolism | ||||
Reactome | SHC1 events in ERBB2 signaling | ||||
PLCG1 events in ERBB2 signaling | |||||
PIP3 activates AKT signaling | |||||
GRB2 events in ERBB2 signaling | |||||
PI3K events in ERBB2 signaling | |||||
Constitutive Signaling by Aberrant PI3K in Cancer | |||||
Sema4D induced cell migration and growth-cone collapse | |||||
RAF/MAP kinase cascade | |||||
WikiPathways | DNA Damage Response (only ATM dependent) | ||||
ErbB Signaling Pathway | |||||
EGF/EGFR Signaling Pathway | |||||
Focal Adhesion | |||||
Extracellular vesicle-mediated signaling in recipient cells | |||||
Bladder Cancer | |||||
Signaling by ERBB2 | |||||
Integrated Pancreatic Cancer Pathway | |||||
Signaling Pathways in Glioblastoma | |||||
Leptin signaling pathway | |||||
miR-targeted genes in muscle cell - TarBase | |||||
Semaphorin interactions | |||||
References | |||||
Ref 467601 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4265). | ||||
Ref 468138 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5046). | ||||
Ref 468150 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5082). | ||||
Ref 521628 | ClinicalTrials.gov (NCT00102895) A Research Study of CP-724,714 in Patients With HER2 Overexpressing Metastatic Breast Cancer. U.S. National Institutes of Health. | ||||
Ref 522127 | ClinicalTrials.gov (NCT00535522) A Safety and Pharmacokinetic Study of TAK-285 in Patients With Advanced Cancer. U.S. National Institutes of Health. | ||||
Ref 522319 | ClinicalTrials.gov (NCT00676299) A Safety and Dose-finding Study of JNJ-26483327, a Drug in Development for Cancer, for Patients With Advanced and/or Refractory Solid Malignancies.. U.S. National Institutes of Health. | ||||
Ref 522608 | ClinicalTrials.gov (NCT00862524) A Study of ARRY-334543 and Gemcitabine in Patients With Advanced Cancer and Pancreatic Cancer. U.S. National Institutes of Health. | ||||
Ref 522883 | ClinicalTrials.gov (NCT01027650) Safety and Efficacy of AGN208397 in the Treatment of Macular Edema Associated With Retinal Vein Occlusion (RVO). U.S. National Institutes of Health. | ||||
Ref 523092 | ClinicalTrials.gov (NCT01152398) A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Breast Cancer After Adjuvant Therapy. U.S. National Institutes of Health. | ||||
Ref 523370 | ClinicalTrials.gov (NCT01301911) Study of Cipatinib in Patients With HER2 Positive or Uncertain Advanced Breast Cancer. U.S. National Institutes of Health. | ||||
Ref 523378 | ClinicalTrials.gov (NCT01304797) Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer. U.S. National Institutes of Health. | ||||
Ref 523475 | ClinicalTrials.gov (NCT01353222) DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma. U.S. National Institutes of Health. | ||||
Ref 523496 | ClinicalTrials.gov (NCT01360554) ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer. U.S. National Institutes of Health. | ||||
Ref 523579 | ClinicalTrials.gov (NCT01409343) TrasGEX Dose Escalation Study. U.S. National Institutes of Health. | ||||
Ref 523700 | ClinicalTrials.gov (NCT01479244) Efficacy and Safety Study of NeuVax (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence. U.S. National Institutes of Health. | ||||
Ref 523789 | ClinicalTrials.gov (NCT01526473) A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901. U.S. National Institutes of Health. | ||||
Ref 523940 | ClinicalTrials.gov (NCT01614522) A Clinical Trial Evaluating the Effect of ASLAN001 in Patients With Recurrent/Metastatic Gastric Cancer Whose Tumors Are Either HER-2 Amplified or Co-expressing HER-1and HER-2. U.S. National Institutes of Health. | ||||
Ref 524128 | ClinicalTrials.gov (NCT01729884) Vaccine Therapy in Treating Patients With Stage IV Hormone Receptor Positive Breast Cancer. U.S. National Institutes of Health. | ||||
Ref 524196 | ClinicalTrials.gov (NCT01774851) A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach. U.S. National Institutes of Health. | ||||
Ref 524257 | ClinicalTrials.gov (NCT01828021) Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer. U.S. National Institutes of Health. | ||||
Ref 524300 | ClinicalTrials.gov (NCT01858116) PET Study of Breast Cancer Patients Using [68Ga]ABY-025. U.S. National Institutes of Health. | ||||
Ref 524352 | ClinicalTrials.gov (NCT01895491) Safety Study of VM206RY in Subjects With Expression of HER2 in Breast Cancer. U.S. National Institutes of Health. | ||||
Ref 524395 | ClinicalTrials.gov (NCT01921335) ARRY-380 + Trastuzuamab for Breast w/ Brain Mets. U.S. National Institutes of Health. | ||||
Ref 524722 | ClinicalTrials.gov (NCT02117167) Intergroup Trial UNICANCER UC 0105-1305/ IFCT 1301: Efficacy of Targeted Drugs Guided by Genomic Profils in Metastatic NSCLC Patients. U.S. National Institutes of Health. | ||||
Ref 524830 | ClinicalTrials.gov (NCT02187744) A Study Of PF-05280014 Or Trastuzumab Plus Taxotere And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04). U.S. National Institutes of Health. | ||||
Ref 524875 | ClinicalTrials.gov (NCT02216916) Phase II Trial of HM781-36B in Patients With Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) After Failure of or Unfit for Platinum-containing Therapy. U.S. National Institutes of Health. | ||||
Ref 525738 | Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions. J Med Chem. 2000 Apr 6;43(7):1380-97. | ||||
Ref 525850 | Development of a cancer vaccine: peptides, proteins, and DNA. Cancer Chemother Pharmacol. 2000;46 Suppl:S77-82. | ||||
Ref 528260 | Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2006 Jun 20;24(18):2786-92. | ||||
Ref 529707 | Ertumaxomab: a trifunctional antibody for breast cancer treatment. Expert Opin Investig Drugs. 2008 Oct;17(10):1553-8. | ||||
Ref 529823 | BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors. Curr Opin Investig Drugs. 2008 Dec;9(12):1336-46. | ||||
Ref 531718 | Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol. 2011 Nov 29;9(1):16-32. | ||||
Ref 531972 | Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling. MAbs. 2012 Sep-Oct;4(5):614-22. | ||||
Ref 532156 | A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer. Breast Cancer Res Treat. 2013 Jan;137(2):471-82. | ||||
Ref 532301 | AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. J Clin Oncol. 2013 May 10;31(14):1719-25. | ||||
Ref 532320 | Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013 May;14(6):461-71. | ||||
Ref 532548 | Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer. Cancer. 2014 Mar 1;120(5):642-51. | ||||
Ref 533101 | A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2015 Apr 1;21(7):1566-73. | ||||
Ref 536361 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20. | ||||
Ref 538585 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 022059. | ||||
Ref 538586 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 022059. | ||||
Ref 541010 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5667). | ||||
Ref 541018 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5675). | ||||
Ref 541034 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5692). | ||||
Ref 541276 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6011). | ||||
Ref 542446 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7422). | ||||
Ref 542628 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7645). | ||||
Ref 542630 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7647). | ||||
Ref 542691 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7717). | ||||
Ref 542808 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7883). | ||||
Ref 542826 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7903). | ||||
Ref 543243 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8686). | ||||
Ref 546750 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010108) | ||||
Ref 547786 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019257) | ||||
Ref 548009 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021154) | ||||
Ref 548526 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026315) | ||||
Ref 548761 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028450) | ||||
Ref 549995 | Journal of Clinical Oncology, 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition), Vol 26, No 15S (May 20 Supplement), 2008: 3034. | ||||
Ref 523789 | ClinicalTrials.gov (NCT01526473) A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901. U.S. National Institutes of Health. | ||||
Ref 525850 | Development of a cancer vaccine: peptides, proteins, and DNA. Cancer Chemother Pharmacol. 2000;46 Suppl:S77-82. | ||||
Ref 526063 | Use of anti-CD3 x anti-HER2/neu bispecific antibody for redirecting cytotoxicity of activated T cells toward HER2/neu+ tumors. J Hematother Stem Cell Res. 2001 Apr;10(2):247-60. | ||||
Ref 526072 | Bioorg Med Chem Lett. 2001 Jun 4;11(11):1401-5.Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2. | ||||
Ref 527947 | Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Clin Breast Cancer. 2005 Dec;6(5):425-32. | ||||
Ref 528989 | Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer. J Clin Oncol. 2007 Aug 20;25(24):3680-7. | ||||
Ref 529707 | Ertumaxomab: a trifunctional antibody for breast cancer treatment. Expert Opin Investig Drugs. 2008 Oct;17(10):1553-8. | ||||
Ref 530257 | N-terminally LRMK-linked HER-2 peptides, AE-37 [p776(774-788)] and AE-47 [Ava-F7(776-788)], aid differentiation of E75-TCR+CD8+ cells to perforin-positive cells. Anticancer Res. 2009 Jul;29(7):2427-35. | ||||
Ref 530980 | Targeting of HER2-expressing tumors using 111In-ABY-025, a second-generation affibody molecule with a fundamentally reengineered scaffold. J Nucl Med. 2010 Jul;51(7):1131-8. | ||||
Ref 531542 | Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models. Int J Cancer. 2012 May 15;130(10):2445-54. | ||||
Ref 531718 | Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol. 2011 Nov 29;9(1):16-32. | ||||
Ref 531972 | Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling. MAbs. 2012 Sep-Oct;4(5):614-22. | ||||
Ref 532308 | Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives. Ann Oncol. 2013 Jul;24(7):1740-8. | ||||
Ref 532798 | The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax?? in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response. Immunotherapy. 2014;6(5):519-31. | ||||
Ref 532875 | Comparative nonclinical assessments of the proposed biosimilar PF-05280014 and trastuzumab (Herceptin(?)). BioDrugs. 2014 Oct;28(5):451-9. | ||||
Ref 532879 | A new hope in immunotherapy for malignant gliomas: adoptive T cell transfer therapy. J Immunol Res. 2014;2014:326545. | ||||
Ref 533101 | A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2015 Apr 1;21(7):1566-73. | ||||
Ref 533224 | Whole-body organ-level and kidney micro-dosimetric evaluations of (64)Cu-loaded HER2/ErbB2-targeted liposomal doxorubicin ((64)Cu-MM-302) in rodents and primates. EJNMMI Res. 2015 Apr 14;5:24. | ||||
Ref 535355 | Anti-ErbB-2 monoclonal antibodies and ErbB-2-directed vaccines. Cancer Immunol Immunother. 2002 Jan;50(11):569-87. Epub 2001 Nov 24. | ||||
Ref 535479 | A new human antitumor immunoreagent specific for ErbB2. Clin Cancer Res. 2002 Jun;8(6):1710-9. | ||||
Ref 535660 | Knockouts model the 100 best-selling drugs--will they model the next 100? Nat Rev Drug Discov. 2003 Jan;2(1):38-51. | ||||
Ref 535976 | Her2/neu is not a commonly expressed therapeutic target in melanoma -- a large cohort tissue microarray study. Melanoma Res. 2004 Jun;14(3):207-10. | ||||
Ref 536331 | Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007 Jan;12(1-2):34-42. Epub 2006 Nov 28. | ||||
Ref 536448 | Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med. 2007 Jul 5;357(1):39-51. | ||||
Ref 536474 | A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. | ||||
Ref 537224 | Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7. | ||||
Ref 542446 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7422). | ||||
Ref 544199 | Immunotoxins and Anticancer Drug Conjugate Assemblies: The Role of the Linkage between Components. Toxins (Basel) 2011 July; 3(7): 848-883. | ||||
Ref 544225 | Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcgamma receptor binding properties. Breast Cancer Res. 2011; 13(6): R123. | ||||
Ref 544342 | Cancer therapy with bispecific antibodies: Clinical experience. Curr Opin Mol Ther. 2010 June; 12(3): 340-349. | ||||
Ref 549731 | ARRY-380, a Potent, Small Molecule Inhibitor of ErbB2, Increases Survival in Intracranial ErbB2+ Xenograft Models in Mice | ||||
Ref 550119 | WO patent application no. 2005,0443,02, Selective erbb2 inhibitor/anti-erbb antibody combinations in the treatment of cancer. | ||||
Ref 550178 | WO patent application no. 2014,1441,21, Classification and actionability indices for lung cancer. | ||||
Ref 550278 | Characterization of AZD8931, a potent reversible small molecule inhibitor against epidermal growth factor receptor (EGFR), erythroblastic leukemia viral oncogene homolog 2 (HER2) and 3 (HER3) with a unique and balanced pharmacological profile. J Clin Oncol 27:15s, 2009. | ||||
Ref 889442 | Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. doi: 10.1038/nrd4478. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.